8th IC-3Rs Symposium 2025

After completing a Master’s degree in Biomedical Sciences at the University of Mons and gaining initial experience in clinical trials at the Military Hospital in Brussels, Maude Everaert joined the Vrije Universiteit Brussel (VUB) in 2022 within the In Vitro Toxicology and Dermato-Cosmetology (IVTD) Department. 

She works as a scientist on the RE-Place Project, which aims to centralize Belgian expertise in alternative methods to animal testing in a central database. Her responsibilities include expanding and maintaining the database, updating the project website, and engaging with the Belgian scientific community through events and outreach to increase the visibility of the project.

Reyk studied biotechnology with a focus on medical biotechnology. He received his doctorate degree (summa cum laude) in biotechnology from the Technische Universität Berlin. Early in his career, his research activities focused on adult human stem cells and their application in cell therapies. During his stay at the Department of Medical Biotechnology at TU Berlin he broadened his research activities toward the development of complex 3D tissue models for substance testing.

In 2010, Dr. Horland joined the “Multi-Organ-Chip” project which was awarded funding by the highly prestigious GO-BIO grant of the German Federal Ministry of Education and Research (BMBF). His research responsibilities focused on various aspects of tissue engineering, e.g. in vitro blood vessels for drug screening.

Between 2012 and 2015, Reyk was responsible for all Business Development activities of TissUse GmbH, a spin-off company dedicated to commercializing the results of the GO-BIO “Multi-Organ-Chip” project. There he succeeded in acquiring clients from pharma and cosmetics industry as early adopters of the technology while further developing and strengthening the contract service panel of TissUse. He devised and supervised TissUse HUMIMIC product launch campaign, introducing one of the first Organ-on-a-Chip products to the market in 2014.

In 2015, Dr. Horland was promoted to senior management of TissUse as VP of Business Development. Under his leadership, the company has seen a remarkable annual sales growth rate utilizing its hybrid business model approach of offering customized services and highly innovative products to clients worldwide.

Dr. Horland was appointed CEO of TissUse in October 2020. His business network includes leading pharmaceutical and consumer product companies as well as regulatory authorities and outstanding research institutions worldwide.

coming soon

Quinten Marcelis is currently a Toxicologist at Procter & Gamble, having joined the company in 2024. In this role within the Global Product Stewardship team, he has global responsibility for human safety of Hard Surface Cleaners, including products such as Mr. Propre and Viakal. He is also an active member of the P&G Contact Dermatitis Team, working to ensure the safety of P&G’s product portfolio.

Prior to this position, Quinten completed a PhD at VUB, at the In VitroToxico-Dermatocosmetology Department. His research, conducted in collaboration with Sciensano, centered on developing a generic safety assessment strategy for feminine intimate products. This work addressed critical needs from both consumers, industry and regulators regarding chemicals in menstrual hygiene products. 

Quinten has presented his PhD research at various (inter)national conferences and poster sessions, contributing to the dialogue on safety assessment methodologies.

Albert Ali Salah is a professor and chair of Social and Affective Computing at the Information and Computing Sciences Department of Utrecht Univ. He obtained his PhD in 2007 from Bogazici University, and worked at CWI, University of Amsterdam, Nagoya University, and Bogazici University, before initiating the Social and Affective Computing group at Utrecht. His research is broad, but mainly uses pattern recognition and machine learning for computer analysis of human behavior. He is a member of the AI and Animal Welfare Lab at Utrecht University, which is a collaboration between ICS and Veterinary Sciences. He currently serves in the Steering Boards of ACM ICMI and IEEE FG conferences, as an associate editor of journals Pattern Recognition and Int. Journal on Human-Computer Studies, and as VP Conferences for the IEEE Biometrics Council. He is a Senior Member of IEEE and ACM.

Dr. Thomas Steger-Hartmann (VP) led the department Investigational Toxicology and subsequently the In Vitro Safety Subcluster at Bayer AG, Pharmaceuticals, Germany until September 2024. Thomas has more than 29 years of experience in the field of preclinical assessment of pharmaceuticals. He is a trained biologist with a diploma from the University of Freiburg i.Br., an M.Sc. degree from the University of Michigan and a PhD from the University of Freiburg i.Br., Germany. He is a Eurotox registered toxicologist.

Thomas was deputy leader of two European Innovative Medicines Initiative (IMI) projects (eTox and eTransafe) which focussed on data science approaches for preclinical safety assessment. Since September 2024 Thomas leads a a new consortium under the Innovative Health Initiative (IHI) for the advancement of virtual control groups with the name VICT3R (“VICTER”), contributing to the reduction of animal use in safety studies.

Dr. Esther Wenzel is COO and Co-Founder of Abcalis GmbH, a biotechnology spin-off from TU Braun-schweig specializing in the production of fully animal-free antibodies using phage display. She holds a PhD in Biotechnology and brings over two decades of experience in diagnostic test development, cell culture, and innovative animal-free techniques, including 3D cell cultures and spheroids as alterna-tives to animal tissue.

Since the early 2000s, Dr. Wenzel has been committed to advancing non-animal methods in biomedi-cal research. In 2016, she developed fully human, animal-free antibodies against diphtheria toxin, currently under FDA review as a replacement for equine serum therapeutics. She co-invented Mul-ticlonal Antibodies, a standardized, animal-free alternative to polyclonal antibodies, and established high-throughput platforms for functional antibody testing.

To bring these innovations to market, Dr. Wenzel co-founded Abcalis GmbH in 2019. The company has received multiple awards for its work, including the 1st ECEAE prize for Animal-free Antibodies, the Lower Saxony Innovation Award and the Braunschweig Start-up Award. Beyond product development, Dr. Wenzel also offers consulting services to help laboratories transition to animal-origin-free research — supporting ethical, scalable, and reproducible scientific solutions.